16 December 2020 - Late treatment study
Prevalence and 30-day mortality in hospitalized patients with COVID-19 and prior lung diseases
et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.11.012 (Peer Reviewed)
47% lower mortality with HCQ/CQ. Retrospective 1,271 patients with lung disease in Canada, China, Cuba, Ecuador, Germany, Italy and Spain, 83% treated with HCQ/CQ.Multivariable Cox regression HCQ/CQ mortality hazard ratio HR 0.53, p < 0.001.
|
risk of death, 47.0% lower, RR 0.53, p < 0.001, treatment 4,854, control 993, adjusted per study.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Signes-Costa et al., 12/16/2020, retrospective, multiple countries, multiple regions, peer-reviewed, 28 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.